These data clearly indicated that S100A4-PPAR-γ upregulation of TAM FAO is through CD36, suggesting that depletion of the S100A4+ subset population of TAMs has highly promising therapeutic potential in cancer therapy. The gene discussed is CD36; the disease is cancer.